Complete if Known Substitute for form 1449A/PTO Application Number 10/709 801 INFORMATION DISCLOSURE Filing Date May 28, 2004 STATEMENT BY APPLICANT First Named Inventor Caroline Desponts (use as many sheets as necessary) Art I Init 1635 **Examiner Name** Jane J. Zara Sheet of Attorney Docket Number 1 USF.212XZ1T 2

			U.S. PATENT DO	OCUMENTS	
Examiner Cite Initials* No. 1		Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/JZ/	/JZ/ U1 US-2003/01		07-31-2003	Fosnaugh et al.	All
	U2	US-2003/0166282 A1	09-04-2003	Brown et al.	All
	U3	US-2004/0259247 A1	12-23-2004	Tuschl et al.	All
	U4	US-2007/0224124 A1	03-19-2007	Kerr et al.	All
	U5	US-2004/0235765 A1	11-25-2004	Kerr et al.	All
	U6	US-2005/0054103 A1	03-10-2005	Peled et al.	All
V	U7	US-11/451,004	06-12-2006	Kerr et al. (application)	All
	U8	US-			
	U9	US-			

			PATENT DOCU	JMENTS			
Examiner Cite Initials* No. 1		Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T'	
/JZ/	F1	WO 2009/042910 A2	04-02-2009	University of South Florida	All		
/JZ/	F2	WO 2002/24233 A2	03-28-2002	University of South Florida	All		
	F3					Г	
	F4					Г	
	F5						
	F6					Γ	
	F7						

Examiner	/Jane Zara/	Date	07/28/2009
Signature	770177	Considered	

"EXAMINET: Initial if reference considered, whether or not obtain is in conformance with MPEP 600. Draw line through citation in roll proformance and not considered include dony of this form with next communication to applicate." Applicant strings children designation number (principal See Kind Colysta or USPTO Patient Documents as asswering to the proformance of the period of the period to the period of the period of the period of the period of the Emperiod of the period o

This collection of information is required by 37 CFR, 197 and 1.98. The information is required to obtain or retain a benefit by the public which is to the land by the USFTO in proceed) an application. Confendinally is operand by 38 U.S. (2. 22 and 37 CFR, 114. This collection in estimated to by busine to proper, including guithering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form ander suggestions for reducing this business, should be sent to the Chief information Officer, U.S. Patient and Trademark Office, P.O. Beatter and P.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO

Sheet

Evaminer

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

2

2

Complete if Known Application Number 10/709.801 Filing Date May 28, 2004 First Named Inventor Caroline Desponts Group Art Unit 1635 Examiner Name Jane J. Zara Attorney Docket Number USF.212XZ1T

		NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.								
/JZ/ R1		ADAMS, A. "RNA Therapeutics: Enter Clinical Trials" The Scientist, 2005, pp. 28-29, Vol. 19, No. 1.								
	R2	BOLLAND, S. et al. "SHIP Modulates Immune Receptor Responses by Regulating Membrane Association of Btk" Immunity, April 1998, pp. 509-516, Vol. 8.								
	R3	DE SOUZA, A.T. et al. "Transcriptional and phenotypic comparisons of <i>Ppara</i> knockout and siRNA knockdown mice" <i>Nucleic Acids Research</i> , 2006, pp. 4486-4494, Vol. 34, No. 16.								
	R4	KRYSTAL, G. et al. "Molecules in focus: SHIPs ahoy" The International Journal of Biochemistry & Cell Biology, 1999, pp. 1007-1010, Vol. 31.								
	R5	NOVINA, C.D. et al. "The RNAi revolution" Nature, July 2004, pp. 161-164, Vol. 430.								
	R6	PAROO, Z. et al. "Challenges for RNAi in vivo" TRENDS in Biotechnology, August 2004, pp. 390-394, Vol. 22, No. 8.								
	R7	PASQUET, J.M. et al. "Phosphatidylinositol 3.4.5-trisphosphate regulates Ca ²¹ entry via Btk in platelets and megakaryocytes without increasing phospholipase C activity" <i>EMBO Journal</i> , June 15, 2000, pp. 2793-2802, Vol. 19, No. 12.								
	R8	SAWYERS, C.L. "Chronic Myeloid Leukemia" <i>The New England Journal of Medicine</i> , April 29, 1999, pp. 1330-1340, Vol. 340, No. 17.								
	R9	Office Action mailed April 7, 2009 in U.S. Serial No. 11/451,004 filed June 12, 2006.								
	R10	Office Action mailed August 5, 2008 in U.S. Serial No. 11/451,004 filed June 12, 2006.								
V R11		Office Action mailed June 5, 2009 in U.S. Serial No. 11/787,084 filed April 13, 2007.								

Signature		/Jane Zara/							Considered 0			7/28/2009					
	Initial it	reference	considered	whether	or not	citation	is in	conformance	with	MPEP			ough citatio	n if not	n conforms	nce	

Data

Hann Zaval

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Exactivities: Initial in deterence considerance, witnesser or not calculate as a consomance with Michigan Unit. Visit like increasing cascins in our momental "Applicants unjoined calculation designation in marker (colorosis)", "Applicants unjoined calculation designation in marker (colorosis)", "Applicants unjoined calculation designation in introduction of information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including the process an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including the process and application. w processy an expension of the completed application of the completed application from the Lagrangian and submitted may be completed application from the lagrangian formation and submitted and an amount of time you require to complete disposition from the lagrangian formation from the amount of time you require to complete disposition from the lagrangian formation from the amount of time you require to complete disposition and consuppositions for reducible busides, should be sent to the Chel middle and an amount of time you require to complete disposition and consuppositions for reducible busides, should be sent to the Chel middle and Chel. Sent and the Chel middle and the Chel Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.